Palindromic Rheumatism: Flares, RA Risk, and Treatment

Palindromic rheumatism is a rare inflammatory condition in which sudden, painful joint flares appear without warning, last hours to days, and then vanish completely, leaving no detectable damage behind. The name comes from the Greek word “palindromos,” meaning to recur, and that recurrence is the defining feature: joints swell, hurt intensely, and then return to normal between episodes as if nothing happened.¹ The condition sits in an uncomfortable gray zone between being a standalone diagnosis and a warning sign that rheumatoid arthritis may be around the corner, and that ambiguity shapes nearly every conversation around it.

What an Attack Looks and Feels Like

A typical flare strikes fast. One or a few joints become swollen, red, warm, and painful over the course of hours. The wrists, knees, and small joints of the hands are most commonly affected, though almost any joint can be involved. Soft tissue around the joints, including tendons and the tissue just under the skin, often swells at the same time, sometimes more prominently than the joint itself. Some people also develop tender nodules near the affected area during a flare.

Episodes usually resolve on their own within one to three days, though some can stretch longer. Between attacks, the joint goes back to feeling completely normal. Standard blood tests for inflammation may be elevated during a flare but return to baseline afterward. X-rays taken between episodes typically show no erosion or lasting joint damage. That pattern of total resolution is what sets palindromic rheumatism apart from other forms of inflammatory arthritis, where inflammation tends to smolder continuously and gradually erode the joint.

The unpredictability is a major burden. Attacks can happen days apart or months apart, with no reliable way to predict when the next one will strike. A qualitative study interviewing people living with the condition found that this uncertainty caused significant activity limitations and psychological distress, with many patients reporting difficulty planning their lives around a disease that could flare at any moment.²

Why Diagnosis Often Takes Years

Because symptoms come and go and leave nothing behind on imaging, palindromic rheumatism is notoriously difficult to diagnose. There is no single blood test that confirms it. Instead, diagnosis relies on the clinical pattern: recurrent self-resolving attacks of joint inflammation with no evidence of joint damage between flares. That means a doctor often needs to observe the pattern over time, which delays the diagnosis considerably.

Making matters worse, patients frequently present to their GP during a flare that resolves before they can get a referral to a rheumatologist. Patients in one study described being told their symptoms were not serious enough to warrant a specialist, or having the complaint attributed to their age rather than a rheumatic condition.³ The fluctuating nature of the symptoms, combined with a general lack of awareness of the condition outside rheumatology, means that some patients bounce between appointments for years before landing on the right diagnosis.

Ultrasound has recently emerged as a useful tool. A prospective study found that during flares, palindromic rheumatism shows a distinctive imaging pattern: inflammation is often located outside the joint capsule, in the soft tissues surrounding the joint, rather than within the joint lining itself. Roughly six in ten patients scanned during a flare showed this extracapsular inflammation, and in most of those cases it occurred without any detectable synovitis inside the joint.⁴ A separate case-control study comparing ultrasound findings in palindromic rheumatism and rheumatoid arthritis found that people with palindromic rheumatism had significantly higher rates of tenosynovitis and soft tissue inflammation, but significantly lower rates of bone erosion compared to those with established RA.⁵ These imaging differences, if captured during a flare, can help clinicians distinguish palindromic rheumatism from early RA.

Will It Turn Into Rheumatoid Arthritis?

This is the question that hangs over every palindromic rheumatism diagnosis, and the honest answer is: it does for some people, but not most. A large population-based study from Taiwan tracked over 4,400 patients with palindromic rheumatism and found that about 13% developed rheumatoid arthritis over the follow-up period.⁶ That risk was dramatically higher than in the general population, but it still means the majority of patients never transitioned to RA. Smaller clinic-based studies tend to report higher progression rates, sometimes reaching one-third, likely because patients tracked in specialty rheumatology clinics tend to have more severe disease than the general population of palindromic rheumatism patients.

Palindromic rheumatism also carries an elevated risk for other autoimmune conditions, not just RA. In that same Taiwanese cohort, about 6% developed Sjögren syndrome and roughly 2.5% developed systemic lupus erythematosus.⁷ Other autoimmune conditions like systemic sclerosis and polymyositis occurred far less frequently. So while RA is the most common destination, it is not the only one.

What Predicts Who Will Progress

Clinicians use two main tools to estimate risk: antibody status and clinical features. Anti-citrullinated protein antibodies (commonly known by the lab test that detects them, anti-CCP) are found in roughly half to two-thirds of palindromic rheumatism patients, which is striking because these antibodies are considered quite specific to rheumatoid arthritis.⁸ Having positive anti-CCP antibodies does increase the odds of eventually developing RA, but the predictive power is weaker than many clinicians assume. In one long-term follow-up study, about 30% of antibody-positive patients progressed to RA over roughly eight years, compared to about 15% of antibody-negative patients. That difference went in the expected direction but was not statistically significant.⁹

The antibody picture gets more nuanced when you look at the specific types of anti-citrullinated antibodies, not just whether the general test is positive or negative. A case-control study found that palindromic rheumatism patients had fewer varieties of these antibodies compared to RA patients. The average number of different antibody specificities was lower in palindromic rheumatism, and a significantly higher proportion of palindromic rheumatism patients who tested positive on the standard screening test actually had no detectable antibodies when tested against a wider panel of targets.¹⁰ This suggests the autoimmune response in palindromic rheumatism may be narrower and less mature than in RA, which could help explain why many antibody-positive patients never progress.

Beyond antibodies, a multivariate analysis identified three independent predictors of a worse disease course: being 40 or younger at onset, not sticking to prescribed therapy, and having involvement of the small finger joints known as the proximal interphalangeal joints. Each of these roughly doubled to quadrupled the risk of treatment failure on its own.¹¹

Probably Not One Disease

One of the more interesting developments in palindromic rheumatism research is the growing recognition that the label may actually cover several distinct conditions that happen to look similar on the surface. A study that tested palindromic rheumatism patients for mutations in the MEFV gene, which is associated with familial Mediterranean fever and other autoinflammatory conditions, found that about a quarter of patients carried at least one MEFV mutation.¹² These patients looked quite different from the rest: they tended to be younger at onset, had very short attacks lasting under three days, favored the knee over the small hand joints, and were more likely to experience extra-articular features like fever and abdominal pain. They also responded well to colchicine, a drug typically used for gout and autoinflammatory conditions rather than autoimmune ones.

Based on genetic and antibody testing, the same study proposed four distinct groups. One group carried MEFV mutations and behaved more like an autoinflammatory disease. A second group was antibody-positive and behaved more like pre-RA, with nearly half eventually meeting criteria for rheumatoid arthritis. A third group, the largest at about half of all patients, was negative for both markers and was the most clinically heterogeneous. A fourth, smaller group carried MEFV mutations alongside an already-diagnosed immune-inflammatory disease.¹³

An earlier study had already noticed that MEFV mutations were far more common among antibody-negative palindromic rheumatism patients than antibody-positive ones, with roughly 22% of the antibody-negative group carrying mutations compared to about 5% of the antibody-positive group.¹⁴ This reinforces the idea that antibody-negative palindromic rheumatism may be a fundamentally different condition from antibody-positive palindromic rheumatism, with the former sitting closer to autoinflammatory diseases and the latter sitting closer to RA. The practical implication is that treatment strategies may need to differ: colchicine for the autoinflammatory subset, disease-modifying antirheumatic drugs for the autoimmune subset.

What Happens Inside the Joint During a Flare

Biopsy and fluid samples taken from joints during palindromic flares show inflammation, but a different kind than what you would see in established RA. An early histological study found that synovial biopsies during episodes showed a superficial inflammatory pattern with prominent blood vessel changes, including electron-dense deposits in vessel walls suggestive of circulating immune complexes. Immune cells were present, but mononuclear cells rather than the aggressive inflammatory cells typical of RA predominated in many samples.¹⁵ Critically, these biopsy findings did not predict which patients would eventually develop RA and which would not, limiting the usefulness of synovial biopsy as a prognostic tool.

Treatment Options

There is no universally agreed-upon treatment protocol for palindromic rheumatism, partly because randomized controlled trials have been scarce until recently. Most treatment evidence comes from retrospective studies and case series, and a systematic review confirmed that the literature remains thin.¹⁶ That said, there is a reasonable consensus on first-line treatment.

Hydroxychloroquine, an antimalarial drug that also has immunomodulatory properties, is the most commonly used long-term therapy. Systematic reviews have found that it reduces the frequency of flares and may delay progression to RA, though the evidence supporting the latter benefit is modest.¹⁷ For acute flares, nonsteroidal anti-inflammatory drugs and short courses of corticosteroids are commonly used to manage pain and swelling, though these are symptomatic treatments rather than disease-modifying ones.

One study that applied a tight-control strategy, monitoring patients closely and adjusting treatment aggressively to suppress flares, found that this approach could control attacks and appeared to reduce progression to RA.¹⁸ This approach mirrors how early RA is increasingly managed, with the idea that suppressing inflammation early and completely prevents the disease from taking hold.

Abatacept as a Potential Step Up

A randomized trial published in Nature Medicine compared abatacept, a biologic drug that blocks a specific immune cell signaling pathway, against hydroxychloroquine in palindromic rheumatism patients who were at high risk of progressing to RA. Over 24 months, about 21% of the abatacept group developed RA, compared to 50% in the hydroxychloroquine group.¹⁹ The trial was small, with only 70 participants, and open-label, meaning both patients and doctors knew which treatment was being given. But the result was statistically significant and suggests that biologic therapy might genuinely prevent the transition from palindromic rheumatism to RA in high-risk individuals. Whether this becomes standard practice will depend on larger confirmatory trials and cost-benefit considerations, since biologic therapies are far more expensive than hydroxychloroquine.

Colchicine for the Autoinflammatory Subset

For the subset of patients who carry MEFV mutations and whose disease resembles an autoinflammatory condition more than an autoimmune one, colchicine appears to be effective. The subtype study described earlier noted a good response to colchicine in MEFV-positive patients.²⁰ This makes biological sense: colchicine works by dampening the innate immune response, which is the arm of the immune system that drives autoinflammatory diseases, rather than the adaptive immune response involved in autoimmune conditions like RA.

Smoking and Palindromic Rheumatism

Smoking is well established as a risk factor for rheumatoid arthritis, and a similar relationship appears to hold for palindromic rheumatism, at least in the antibody-positive subset. A propensity-score-matched study found that ever having smoked was associated with a significantly increased risk of developing anti-CCP-positive palindromic rheumatism. Among those who already had the diagnosis, smokers also had a lower rate of sustained remission compared to people who had never smoked.²¹ The study did not find significant differences in other clinical features or outcomes between smokers and non-smokers, suggesting that smoking’s main effect is on disease susceptibility and the likelihood of achieving remission rather than on the severity of individual flares.

When It Affects Children

Palindromic rheumatism in children is extremely rare and poorly understood. A study that specifically sought out pediatric cases found only ten patients, with an average age at diagnosis of about eight years. The knees were the most commonly affected joints, and attacks lasted longer than typically described in adults, averaging about 12 days. Only 20% tested positive for rheumatoid factor. One of the ten children progressed to polyarticular juvenile idiopathic arthritis after three years. Six of ten were still having attacks at their last follow-up, and only three achieved long-term remission.²² The numbers are too small to draw firm conclusions, but the finding that most children continued to have active disease challenges any assumption that palindromic rheumatism in younger patients is a benign, self-limiting condition.

Dietary Triggers and Self-Management

Because orthodox treatment options remain limited, many patients explore dietary changes on their own. A controlled study looked at 16 palindromic rheumatism patients who kept detailed food diaries alongside records of their flares. In about a third of them, episodes appeared to be triggered by specific foods consumed within 36 hours before the attack. The culprits varied by individual: fish, eggs, canned vegetables, and processed cheese were all implicated. When the offending food was removed from the diet, two patients experienced complete cessation of attacks, while three others had milder and less frequent episodes. Four patients were rechallenged with the suspected food, and in every case the flare returned.²³

The study was small, and dietary triggers clearly did not apply to the majority of participants. But for the subset in whom food played a role, the effect was consistent enough to be clinically meaningful. Keeping a food diary alongside a flare diary for several months is a low-cost, low-risk approach that some rheumatologists recommend as a supplemental strategy, though it should not replace medical treatment for patients at risk of progressing to RA.

The 1940 Origin and a Condition Still Being Defined

The condition was first described in 1940 by Philip Hench and Edward Rosenberg at the Mayo Clinic, based on 34 patients they had been tracking since 1928.²⁴ Hench, who would later win a Nobel Prize for discovering cortisone’s effect on rheumatoid arthritis, chose the name “palindromic” to capture the defining feature: the disease runs its course and then returns to the starting point, again and again. More than 80 years later, the condition still lacks formal classification criteria, and there is no entry for it in the standard classification systems used for rheumatic diseases. It remains defined mainly by what it does: episodic inflammation that resolves completely between attacks. Whether it will eventually be broken up into the subtypes that emerging genetic and immunological research suggests, or whether it will retain its identity as a single clinical entity with variable outcomes, is one of the genuinely open questions in rheumatology. The research is still catching up with a condition that has been observed for nearly a century but studied with modern tools for only the last two decades.